More than 300 million people, or 5% of the worldwide population, are living with a rare disease, defined as a disease that affects fewer than 200,000 people at any given time. Those with rare diseases are often misdiagnosed or not diagnosed at all, which makes it nearly impossible to find the right care.
CND Life Sciences is proud to offer clinicians the Syn-One Test™ to support the diagnosis of two rare diseases, multiple system atrophy and pure autonomic failure. Both of these neurological conditions are marked by the presence of alpha-synuclein, an abnormally folded protein that clumps together in nerve cells throughout the body. However, the search for a reliable and practical way to detect alpha-synuclein has been challenging.
Building upon a decade of research, the founders of CND developed the Syn-One Test—the only commercially available diagnostic tool that uses skin biopsy samples to detect alpha-synuclein in cutaneous nerve fibers. The procedure is minimally invasive, and the results can help ensure that patients are properly diagnosed so they can receive the type of care they need.
Learn about Rare Disease Day at https://www.rarediseaseday.org/